Roche’s Push In Cancer Immunotherapy: An Interview With New Exec Hy Levitsky
This article was originally published in The Pink Sheet Daily
“Cancer immunology will play a far greater role than it ever has within the [Roche Pharma Research and Early Development Organization] and we hope there will be synergies we can exploit with other treatment modalities under development at Roche,” Levitsky says.
You may also be interested in...
Combining immatics’ tumor-associated peptide vaccines with Roche’s checkpoint inhibitors is expected to provide a promising approach to the development of novel combination immunotherapies.
No longer the odd cousins of traditional pharmaceutical applications, a host of therapeutic cancer vaccines is working through late-stage trials with real, life-extending data already reported and the potential to create a lot of action in the oncology sector.
Problems that led to the capsizing of Dendreon Corp.’s Provenge prostate cancer immunotherapy are particular to the company and product, some cancer vaccine makers are quick to say. Nevertheless, what the Street saw as a commercial disaster for the pioneering treatment bears lessons for those who follow in the budding space.